Literature DB >> 10792203

Nonspecific binding of drugs to human liver microsomes.

J A McLure1, J O Miners, D J Birkett.   

Abstract

AIMS: To characterize the nonspecific binding to human liver microsomes of drugs with varying physicochemical characteristics, and to develop a model for the effect of nonspecific binding on the in vitro kinetics of drug metabolism enzymes.
METHODS: The extent of nonspecific binding to human liver microsomes of the acidic drugs caffeine, naproxen, tolbutamide and phenytoin, and of the basic drugs amiodarone, amitriptyline and nortriptyline was investigated. These drugs were chosen for study on the basis of their lipophilicity, charge, and extent of ionization at pH 7.4. The fraction of drug unbound in the microsomal mixture, fu(mic), was determined by equilibrium dialysis against 0.1 M phosphate buffer, pH 7.4. The data were fitted to a standard saturable binding model defined by the binding affinity KD, and the maximum binding capacity Bmax. The derived binding parameters, KD and Bmax, were used to simulate the effects of saturable nonspecific binding on in vitro enzyme kinetics.
RESULTS: The acidic drugs caffeine, tolbutamide and naproxen did not bind appreciably to the microsomal membrane. Phenytoin, a lipophilic weak acid which is mainly unionized at pH 7. 4, was bound to a small extent (fu(mic) = 0.88) and the binding did not depend on drug concentration over the range used. The three weak bases amiodarone, amitriptyline and nortriptyline all bound extensively to the microsomal membrane. The binding was saturable for nortriptyline and amitriptyline. Bmax and KD values for nortriptyline at 1 mg ml-1 microsomal protein were 382 +/- 54 microM and 147 +/- 44 microM, respectively, and for amitriptyline were 375 +/- 23 microM and 178 +/- 33 microM, respectively. Bmax, but not KD, varied approximately proportionately with the microsome concentration. When KD is much less than the Km for a reaction, the apparent Km based on total drug can be corrected by multiplying by fu(mic). When the substrate concentration used in a kinetic study is similar to or greater than the KD (Km >/= KD), simulations predict complex effects on the reaction kinetics. When expressed in terms of total drug concentrations, sigmoidal reaction velocity vs substrate concentration plots and curved Eadie Hofstee plots are predicted.
CONCLUSIONS: Nonspecific drug binding in microsomal incubation mixtures can be qualitatively predicted from the physicochemical characteristics of the drug substrate. The binding of lipophilic weak bases is saturable and can be described by a standard binding model. If the substrate concentrations used for in vitro kinetic studies are in the saturable binding range, complex effects are predicted on the reaction kinetics when expressed in terms of total (added) drug concentration. Sigmoidal reaction curves result which are similar to the Hill plots seen with cooperative substrate binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792203      PMCID: PMC2014956          DOI: 10.1046/j.1365-2125.2000.00193.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation.

Authors:  L K Ludden; T M Ludden; J M Collins; H S Pentikis; J M Strong
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.

Authors:  G E Schwab; J L Raucy; E F Johnson
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats.

Authors:  M Chiba; S Fujita; T Suzuki
Journal:  J Pharm Sci       Date:  1990-04       Impact factor: 3.534

5.  E- and Z-10-hydroxylation of nortriptyline by human liver microsomes--methods and characterization.

Authors:  B Mellström; L Bertilsson; C Birgersson; M Göransson; C von Bahr
Journal:  Drug Metab Dispos       Date:  1983 Mar-Apr       Impact factor: 3.922

6.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

Authors:  J O Miners; K J Smith; R A Robson; M E McManus; M E Veronese; D J Birkett
Journal:  Biochem Pharmacol       Date:  1988-03-15       Impact factor: 5.858

7.  Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

Authors:  J O Miners; S Coulter; R H Tukey; M E Veronese; D J Birkett
Journal:  Biochem Pharmacol       Date:  1996-04-26       Impact factor: 5.858

8.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

Authors:  Y F Ueng; T Kuwabara; Y J Chun; F P Guengerich
Journal:  Biochemistry       Date:  1997-01-14       Impact factor: 3.162

9.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

10.  In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.

Authors:  C Bäärnhielm; H Dahlbäck; I Skånberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-08
View more
  28 in total

1.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

2.  S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.

Authors:  Kushari Bowalgaha; David J Elliot; Peter I Mackenzie; Kathleen M Knights; Stellan Swedmark; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

3.  Ste24p Mediates Proteolysis of Both Isoprenylated and Non-prenylated Oligopeptides.

Authors:  Emily R Hildebrandt; Buenafe T Arachea; Michael C Wiener; Walter K Schmidt
Journal:  J Biol Chem       Date:  2016-04-29       Impact factor: 5.157

4.  The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

Authors:  K Bowalgaha; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

5.  Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2019-05-01       Impact factor: 3.922

6.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.

Authors:  Matteo Gianella-Borradori; Ivy Christou; Carole J R Bataille; Rebecca L Cross; Graham M Wynne; David R Greaves; Angela J Russell
Journal:  Bioorg Med Chem       Date:  2014-11-08       Impact factor: 3.641

7.  Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.

Authors:  Jennypher Mudunuru; Chen Ren; David R Taft; Manoj Maniar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

8.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

9.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.